Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Endocrine|December 11, 2003
Alzheimer's disease: pathophysiological implications of measurement of plasma cortisol, plasma dehydroepiandrosterone sulfate, and lymphocytic corticosteroid receptorsDecio Armanini, Franco Vecchio, Alfonso Basso, et al.
The Journal of Clinical Endocrinology and Metabolism|April 9, 2004
Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytesLorenzo A Calò, Francesca Zaghetto, Elisa Pagnin, et al.
Diabetes Care|March 1, 2005
Autoantibodies against oxidized LDLs and atherosclerosis in type 2 diabetesFrancesco Piarulli, Annunziata Lapolla, Giovanni Sartore, et al.
International Journal of Molecular Medicine|September 12, 2006
Identification of the mineralocorticoid receptor in human spermatozoaCristina Fiore, Daniele Sticchi, Donatella Pellati, et al.
Frontiers in Oncology|November 29, 2023
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective studyFabrizio Nelli, Agnese Fabbri, Andrea Botticelli, et al.
Current Oncology (Toronto, Ont.)|May 26, 2023
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third StudyFabrizio Nelli, Agnese Fabbri, Antonella Virtuoso, et al.
Cancer Immunology, Immunotherapy : CII|July 10, 2023
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitorsFabrizio Nelli, Diana Giannarelli, Agnese Fabbri, et al.
Cancers|July 29, 2023
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile StudyFabrizio Nelli, Carlo Signorelli, Agnese Fabbri, et al.
Scientific Reports|December 19, 2022
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patientsEnzo Maria Ruggeri, Fabrizio Nelli, Diana Giannarelli, et al.
Clinical and Experimental Medicine|January 20, 2024
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective studyFabrizio Nelli, Agnese Fabbri, Antonella Virtuoso, et al.
Pageof 5